山西医药杂志
山西醫藥雜誌
산서의약잡지
Shanxi Medical Journal
2015年
17期
1975-1978
,共4页
食管肿瘤%热疗%化学治疗
食管腫瘤%熱療%化學治療
식관종류%열료%화학치료
Esophageal neoplasms%Hyperthermia%Chemotherapy
目的:观察热疗联合化疗对中晚期食管癌患者的疗效及安全性。方法回顾分析我院2008年10月3日至2014年10月9日有明确病理的中晚期食管癌患者136例,按数字表随机原则分组的方法分为单纯化疗组(A 组)和化疗联合热疗组(B 组)。其中 A 组68例,给予紫杉醇175 mg/m2,静脉滴注,第1天,卡培他滨1000 mg/m2,口服,第1~14天,顺铂75 mg/m2,静脉滴注,分为第2~4天,21 d为1个周期,每例患者至少化疗2个周期;B组68例采用同样方案化疗,第1天同时配合全身热疗,使全身温度升至40~42℃,维持90 min。2个周期后观察A组和B组患者的近期疗效及毒副反应。结果 A组中完全缓解(CR)0例,部分缓解(PR)27例,稳定(SD)26例,进展(PD)15例,有效率(CR+ PR)为39.7%;B组中CR 3例,PR 41例,SD 18例,PD 6例,CR+PR为64.7%。2组比较差异有统计学意义(P=0.003)。B组生活质量改善明显高于A组,差异有统计学意义( P=0.002)。Ⅲ度~Ⅳ度肝肾功能损害、骨髓抑制及消化道反应发生率A组分别为16.2%、23.5%及25.0%;B组分别为13.2%、20.6%及30.9%,差异均无统计学意义(肝肾功能损害 P=0.628;骨髓抑制 P=0.679;消化道反应 P=0.444)。结论热疗联合化疗治疗中晚期食管癌,疗效确切,生活质量明显改善,安全性好,值得临床进一步研究和观察。
目的:觀察熱療聯閤化療對中晚期食管癌患者的療效及安全性。方法迴顧分析我院2008年10月3日至2014年10月9日有明確病理的中晚期食管癌患者136例,按數字錶隨機原則分組的方法分為單純化療組(A 組)和化療聯閤熱療組(B 組)。其中 A 組68例,給予紫杉醇175 mg/m2,靜脈滴註,第1天,卡培他濱1000 mg/m2,口服,第1~14天,順鉑75 mg/m2,靜脈滴註,分為第2~4天,21 d為1箇週期,每例患者至少化療2箇週期;B組68例採用同樣方案化療,第1天同時配閤全身熱療,使全身溫度升至40~42℃,維持90 min。2箇週期後觀察A組和B組患者的近期療效及毒副反應。結果 A組中完全緩解(CR)0例,部分緩解(PR)27例,穩定(SD)26例,進展(PD)15例,有效率(CR+ PR)為39.7%;B組中CR 3例,PR 41例,SD 18例,PD 6例,CR+PR為64.7%。2組比較差異有統計學意義(P=0.003)。B組生活質量改善明顯高于A組,差異有統計學意義( P=0.002)。Ⅲ度~Ⅳ度肝腎功能損害、骨髓抑製及消化道反應髮生率A組分彆為16.2%、23.5%及25.0%;B組分彆為13.2%、20.6%及30.9%,差異均無統計學意義(肝腎功能損害 P=0.628;骨髓抑製 P=0.679;消化道反應 P=0.444)。結論熱療聯閤化療治療中晚期食管癌,療效確切,生活質量明顯改善,安全性好,值得臨床進一步研究和觀察。
목적:관찰열료연합화료대중만기식관암환자적료효급안전성。방법회고분석아원2008년10월3일지2014년10월9일유명학병리적중만기식관암환자136례,안수자표수궤원칙분조적방법분위단순화료조(A 조)화화료연합열료조(B 조)。기중 A 조68례,급여자삼순175 mg/m2,정맥적주,제1천,잡배타빈1000 mg/m2,구복,제1~14천,순박75 mg/m2,정맥적주,분위제2~4천,21 d위1개주기,매례환자지소화료2개주기;B조68례채용동양방안화료,제1천동시배합전신열료,사전신온도승지40~42℃,유지90 min。2개주기후관찰A조화B조환자적근기료효급독부반응。결과 A조중완전완해(CR)0례,부분완해(PR)27례,은정(SD)26례,진전(PD)15례,유효솔(CR+ PR)위39.7%;B조중CR 3례,PR 41례,SD 18례,PD 6례,CR+PR위64.7%。2조비교차이유통계학의의(P=0.003)。B조생활질량개선명현고우A조,차이유통계학의의( P=0.002)。Ⅲ도~Ⅳ도간신공능손해、골수억제급소화도반응발생솔A조분별위16.2%、23.5%급25.0%;B조분별위13.2%、20.6%급30.9%,차이균무통계학의의(간신공능손해 P=0.628;골수억제 P=0.679;소화도반응 P=0.444)。결론열료연합화료치료중만기식관암,료효학절,생활질량명현개선,안전성호,치득림상진일보연구화관찰。
Objective To determine the therapeutic efficacy and security of hyperthermia combined with chemotherapy for advanced esophageal carcinoma .Methods One hundred and thirty‐six patients with locally ad‐vanced or metastatic esophageal carcinoma in the duration of Oct .3 ,2008 to Oct .9 ,2013 were enrolled into the study at random .Different chemotherapy regimens were applied in 136 patients with advanced esophageal carcino‐ma .Among them ,68 patients (Group A) receive chemotherapy through vein .The patients received paclitaxel 175 mg/m2 on day 1 ,Capecitabine 1 000 mg/m2 on day1‐14 and Cisplatin 75 mg/m2 on day 2‐4 of 21‐day course .The other 68 patients (Group B) received hyperthermia together with chemotherapy .Hyperthermia was maintained at 40‐42℃ for 90 min .We evaluated the efficacy and toxicity side‐effect after the patients received two courses .Re‐sults In Group A ,the rate of complete remission(CR) was 0 patient ,partial remission(PR) 27 patients ,stable disease(SD) 26 patients ,progressive disease (PD) 15 patients and the overall response rate (CR+ PR) was 39 . 7% ;while in Group B ,the corresponding figures were 3 ,41 ,18 ,6 and 64 .7% ,respectively .There were signif‐icant difference between the two groups (P=0 .003) .Life quality of B group was better than that of A group . There were significant difference between the two groups (P=0 .002) .The rate of grade Ⅲ﹢grade Ⅳ abnormal liver and kidney function ,myelosuppression and gastrointestinal tract reaction was 16 .2% ,23 .5% and 25 .0% in Group A ;while 13 .2% ,20 .6% and 30 .9% in Group B .No significant difference was found between them(P=0 .628 ,P=0 .679 ,P=0 .444) .Conclusion Hyperthermia combined with chemotherapy is efficient and safe for ad‐vanced esophageal carcinoma ,and is worthwhile for further study and observation in clinic .